(Updates with further details and background)
March 20 (Reuters) - Australian Clinical Labs (ACL) said on Monday it will acquire Healius (HLS) through an all-share takeover, valuing the medical center operator at A$1.52 billion ($1.02 billion).
The pathology firm said it will offer 0.74 share for every Healius share. The offer price represents a discount of about 4.2% to Healius' last close.
If the deal is successful, Healius' shareholder will own 68% of the merged entity, the company said in a statement.
In 2020, Healius rejected a $1.3 billion buyout offer from Partners Group, saying at the time it undervalued the medical center operator.
($1 = 1.4896 Australian dollars)
News: ACL UPDATE 1-Australian Clinical Labs offers to buy Healius for $1 billion
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.60 |
Change
-0.030(1.14%) |
Mkt cap ! $510.6M | |||
| Open | High | Low | Value | Volume |
| $2.64 | $2.65 | $2.59 | $901.1K | 345.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18300 | $2.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.62 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2025 (20 minute delay) ? |
| ACL (ASX) Chart |